Use of pristinamycin for infections by gram-positive bacteria: clinical experience at an Australian hospital.
Thirty-six patients were treated with pristinamycin for 46 different microbiological isolates between April 2007 and July 2009. Pathogens included 9 methicillin-resistant Staphylococcus aureus isolates, 13 methicillin-resistant coagulase negative staphylococci, and 9 vancomycin-resistant enterococci. Sites of infections included 12 osteomyelitis cases, 10 prosthetic joints, 4 other prostheses, and 1 epidural abscess. Five patients ceased treatment due to side effects. Ten patients were cured of their infections, and 21 patients had infections successfully suppressed.
Reid
A B
AB
Infectious Diseases Unit, St. Vincent's Hospital, 1 Lochner St., West Hobart, Melbourne, Victoria 7000, Australia. reid.alistair@gmail.com
Daffy
J R
JR
Stanley
P
P
Buising
K L
KL
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001315:Australia; D005260:Female; D006094:Gram-Positive Bacteria / Q000187:drug effects* / Q000472:pathogenicity*; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D006761:Hospitals / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D008875:Middle Aged; D025762:Pristinamycin / Q000627:therapeutic use*; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D025762:Pristinamycin